Siemens Healthineers stock
SHL.DEXETRASiemens Healthineers AG, HealthcareISIN DE000SHL1006WKN SHL100
65Score 65 out of 100, Neutral
Price and trend
79 / 100
Price history
−2.3% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 16% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 7.2% below its 52-week high. Largest decline in 9 years: 50% (December 2021 to May 2026).
Chart figures for advanced users
- SMA 50$44.76
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$42.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$37.16
- The lowest closing price of the last twelve months.
- Resistance$52.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Siemens Healthineers AG belongs to the Medical (Devices) industry (Germany) and, with a market value of $54.55B, is number 6 of 90 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $26.29B (up 1.1% year on year) and earnings of $2.46B (up 3.3%).
- For fiscal 2027, analysts expect on average revenue of $27.9B (up 6.1%) and adjusted earnings per share of $2.63 (down 1.4%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 217 of 714 in Healthcare, median 53.
- The P/E is 22 (Medical (Devices) median 29, own median of recent years 27.2).
- Our model puts fair value at $65.10, with the price 26% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 26% below the fair value of $65.10.Valuation 72
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 83
- Earnings turn into cashFree cash flow 102% of earnings over the last 12 months.Fundamentals 83
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and technical analysis, while growth and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $54.25 and expensive above $81.38 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $65.90 (cash-flow model) and $64.30 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $59.43, at 6.3% it would be $73.54.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 1.1% on the prior year. Revenue has grown solidly since 2015, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 39%, operating 14%, net 9%.
Debt & balance sheet
Fiscal 2026The balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 5 Nov 2026EPS reported $0.78 (expected $0.76)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.630.0%
- Revenue
- $27.9B+0.3%
- Earnings per share
- $2.99+0.1%
- Revenue
- $29.57B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: +5.1%Revenue growth outlook lowered to 3.5% to 4% from 4.5% to 5%; adjusted EPS guidance raised to EUR 2.35 to EUR 2.45, exactly by the amount of tariff refunds received.
“We are lowering the revenue outlook range from 4.5% to 5% growth to now 3.5% to 4%. In addition, we raised the lower end and upper end of the EPS outlook range by EUR 0.15, which is exactly the impact of tariff refunds received in Q3.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q3 2026), read by AI.
What happened at Siemens Healthineers
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Medtronic PlcMDT $129.98B70
- StrykerSYK $121.36B70
- Boston ScientificBSX $65.41B63
- Edwards LifesciencesEW $60.84B76
- GE HealthCare TechnologiesGEHC $37.35B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
- Koninklijke PhilipsPHIA.AS $29.51B56
ETFs that hold Siemens Healthineers
Held by 135 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares TecDAX UCITS ETF (DE)EXIB | 12.74% | 0.51% | €12.44M |
| Xtrackers Euro Stoxx Quality Dividend UCITS ETF 1DDXSA | 2.92% | 0.30% | €792.98M |
| iShares DivDAX UCITS ETF (DE)EXSB | 2.81% | 0.31% | €566.09M |
Show 5 more
| Amundi F.A.Z. 100 UCITS ETFC006 | 2.18% | 0.15% | €103.2M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.95% | 0.49% | €318.39M |
| Deka DAX ex Financials 30 UCITS ETFELF0 | 1.59% | 0.31% | €19.34M |
| Xtrackers DAX ESG Screened UCITS ETF 1DXDDX | 1.44% | 0.09% | €591.73M |
| Amundi DAX 50 ESG II UCITS ETF DistE909 | 1.36% | 0.15% | €323.69M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Nov 2023)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.